STOK
$11.25
Revenue | $2.8Mn |
Net Profits | $-26.96Mn |
Net Profit Margins | -962.1% |
Stoke Therapeutics’s revenue fell -14.29% since last year same period to $2.8Mn in the Q4 2023. On a quarterly growth basis, Stoke Therapeutics has generated -15.3% fall in its revenue since last 3-months.
Stoke Therapeutics’s net profit fell -22.28% since last year same period to $-26.96Mn in the Q4 2023. On a quarterly growth basis, Stoke Therapeutics has generated -9.84% fall in its net profits since last 3-months.
Stoke Therapeutics’s net profit margin fell -42.65% since last year same period to -962.1% in the Q4 2023. On a quarterly growth basis, Stoke Therapeutics has generated -29.68% fall in its net profit margins since last 3-months.
EPS Estimate Current Quarter | -0.61 |
EPS Estimate Current Year | -0.61 |
Stoke Therapeutics’s earning per share (EPS) estimates for the current quarter stand at -0.61 - a 3.17% jump from last quarter’s estimates.
Stoke Therapeutics’s earning per share (EPS) estimates for the current year stand at -0.61.
Earning Per Share (EPS) | -0.6 |
Return on Assets (ROA) | -0.3 |
Return on Equity (ROE) | -0.61 |
Stoke Therapeutics’s earning per share (EPS) jumped 7.69% since last year same period to -0.6 in the Q4 2023. This indicates that the Stoke Therapeutics has generated 7.69% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Stoke Therapeutics’s return on assets (ROA) stands at -0.3.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Stoke Therapeutics’s return on equity (ROE) stands at -0.61.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2023-05-04 | -0.7 | -0.53 | 24.29% |
2023-11-07 | -0.63 | -0.55 | 12.7% |
2023-08-07 | -0.64 | -0.69 | -7.81% |
2024-03-25 | -0.63 | -0.6 | 4.76% |